This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Prednisolone hemisuccinate is a corticosteroid indicated in the treatment of anaphylaxis, asthma, edema, organ rejection, and other indications.
- Generic Name
- Prednisolone hemisuccinate
- DrugBank Accession Number
- DB14633
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for Prednisolone hemisuccinate (DB14633)
- Weight
- Average: 460.523
Monoisotopic: 460.20971799 - Chemical Formula
- C25H32O8
- Synonyms
- (+)-prednisolone hemisuccinate
- Prednisolonbisuccinat
- Prednisolone 21-hemisuccinate
- Prednisolone 21-succinate
- Prednisolone bisuccinate
- Prednisolone hemisuccinate
- Prednisolone hydrogen succinate
- Prednisolone succinate
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Acute adrenal insufficiency •••••••••••• •••••••••• ••••••• ••• •••••••• Treatment of Acute idiopathic thrombocytopenic purpura •••••••••••• •••••••••• ••••••• ••• •••••••• Treatment of Acute severe asthma •••••••••••• •••••••••• ••••••• ••• •••••••• Treatment of Anaphylaxis •••••••••••• •••••••••• ••••••• ••• •••••••• Treatment of Autoimmune hemolytic anemia •••••••••••• •••••••••• ••••••• ••• •••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbemaciclib The metabolism of Abemaciclib can be increased when combined with Prednisolone hemisuccinate. Acalabrutinib The metabolism of Acalabrutinib can be increased when combined with Prednisolone hemisuccinate. Acarbose The risk or severity of hyperglycemia can be increased when Prednisolone hemisuccinate is combined with Acarbose. Aceclofenac The risk or severity of gastrointestinal irritation can be increased when Prednisolone hemisuccinate is combined with Aceclofenac. Acemetacin The risk or severity of gastrointestinal irritation can be increased when Prednisolone hemisuccinate is combined with Acemetacin. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Prednisolone sodium succinate 8223RR9DWF 1715-33-9 FKKAEMQFOIDZNY-CODXZCKSSA-M
Categories
- Drug Categories
- Adrenal Cortex Hormones
- Corticosteroids
- Cytochrome P-450 CYP3A Inducers
- Cytochrome P-450 CYP3A4 Inducers
- Cytochrome P-450 CYP3A4 Inducers (strength unknown)
- Cytochrome P-450 CYP3A5 Inducers
- Cytochrome P-450 CYP3A5 Inducers (strength unknown)
- Cytochrome P-450 Enzyme Inducers
- Fused-Ring Compounds
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Pregnadienes
- Pregnadienetriols
- Pregnanes
- Steroids
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- G7080T74ON
- CAS number
- 2920-86-7
- InChI Key
- APGDTXUMTIZLCJ-CGVGKPPMSA-N
- InChI
- InChI=1S/C25H32O8/c1-23-9-7-15(26)11-14(23)3-4-16-17-8-10-25(32,24(17,2)12-18(27)22(16)23)19(28)13-33-21(31)6-5-20(29)30/h7,9,11,16-18,22,27,32H,3-6,8,10,12-13H2,1-2H3,(H,29,30)/t16-,17-,18-,22+,23-,24-,25-/m0/s1
- IUPAC Name
- 4-{2-[(1R,3aS,3bS,9aR,9bS,10S,11aS)-1,10-dihydroxy-9a,11a-dimethyl-7-oxo-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl]-2-oxoethoxy}-4-oxobutanoic acid
- SMILES
- [H][C@@]12CC[C@](O)(C(=O)COC(=O)CCC(O)=O)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
References
- General References
- BASG Product Information: Prednisolut (prednisolone hemisuccinate) injection [Link]
- External Links
- ChemSpider
- 571099
- ChEBI
- 135745
- ChEMBL
- CHEMBL485659
- ZINC
- ZINC000003881478
- Wikipedia
- Prednisolone
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Injection, powder, for solution Parenteral Injection, powder, for solution Parenteral 1000 mg Injection, powder, for solution Parenteral 25 mg Injection, powder, for solution Parenteral 250 mg Injection, powder, for solution Parenteral 50 mg Injection, powder, for solution Parenteral 500 mg Injection, powder, for solution Parenteral 1 g - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0483 mg/mL ALOGPS logP 2.05 ALOGPS logP 1.54 Chemaxon logS -4 ALOGPS pKa (Strongest Acidic) 3.66 Chemaxon pKa (Strongest Basic) -2.9 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 7 Chemaxon Hydrogen Donor Count 3 Chemaxon Polar Surface Area 138.2 Å2 Chemaxon Rotatable Bond Count 7 Chemaxon Refractivity 118.54 m3·mol-1 Chemaxon Polarizability 47.52 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-004l-0005900000-7d3ccc2239b7a8daf311 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-004l-0009000000-1895b69bf8c78741393e Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-002f-3527900000-b64e939c7803986a7da2 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-004i-3009000000-85ee46395f6f4eea0377 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-0229-9204100000-127ff55958cbfe6dfb2d Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-08fr-1924100000-3e485c175226aaea056a Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 226.1426145 predictedDarkChem Lite v0.1.0 [M-H]- 198.06438 predictedDeepCCS 1.0 (2019) [M+H]+ 223.4062145 predictedDarkChem Lite v0.1.0 [M+H]+ 199.9037 predictedDeepCCS 1.0 (2019) [M+Na]+ 224.6870145 predictedDarkChem Lite v0.1.0 [M+Na]+ 206.05235 predictedDeepCCS 1.0 (2019)
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inducer
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Dvorak Z, Pavek P: Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35. doi: 10.3109/03602532.2010.484462. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inducer
- General Function
- Oxygen binding
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP3A5
- Uniprot ID
- P20815
- Uniprot Name
- Cytochrome P450 3A5
- Molecular Weight
- 57108.065 Da
References
- Dvorak Z, Pavek P: Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35. doi: 10.3109/03602532.2010.484462. [Article]
Drug created at September 01, 2018 15:16 / Updated at May 14, 2021 01:07